

Improving symptoms of intermittent claudication in patients with erectile dysfunction and peripheral vascular disease: a pilot study assessing the benefit of daily dosing with Cialis (tadalafil) 10 mg

Submission date 18/09/2007	Recruitment status No longer recruiting	☐ Prospectively registered ☐ Protocol
Registration date 05/12/2007	Overall study status Completed	☐ Statistical analysis plan ☐ Results
Last Edited 10/07/2017	Condition category Circulatory System	☐ Individual participant data ☐ Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Graham Jackson

Contact details
Cardiothoracic Centre
6th Floor, East Wing
St Thomas' Hospital
London
United Kingdom
SE1 7EH
+44 (0)20 7188 1055
jean.stagg@gstt.nhs.uk

Additional identifiers

Protocol serial number
GJ001 PVD

Study information

Scientific Title

Improving symptoms of intermittent claudication in patients with erectile dysfunction and peripheral vascular disease: a pilot study assessing the benefit of daily dosing with Cialis (tadalafil) 10 mg

Study objectives

Daily dosing with the Phosphodiesterase type 5 (PDE 5) inhibitor tadalafil (10 mg) (for a 14-day period) may improve symptoms of claudication in patients with erectile dysfunction and peripheral vascular disease.

Ethics approval required

Old ethics approval format

Ethics approval(s)

St Thomas' Hospital Local Research Ethics Committee, 09/01/2007, ref: 06/Q0702/162

Primary study design

Interventional

Study design

Prospective randomised double-blind placebo-controlled cross-over pilot study

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Erectile dysfunction, peripheral vascular disease

Interventions

Suitably screened and consenting patients will undertake an Exercise Tolerance Test (ETT) (modified Bruce protocol). Once baseline is established (two tests, 2 weeks apart), Tadalafil 10 mg daily or placebo will be prescribed for a 14 day period. ETT will then be repeated. A weeks wash-out will be observed. A repeat ETT will be undertaken and the patient prescribed either placebo or tadalafil for a further 14 day period. ETT will be repeated. A final follow up occurs one week after this, and with a one week run in, this makes the total duration of this study 7 weeks.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Tadalafil

Primary outcome(s)

Total number of minutes/seconds on the exercise treadmill. Time to first report of leg pain will be recorded, measured at the end of weeks 3, 4 and 6

Key secondary outcome(s)

Change in score on the Walking Impairment Questionnaire and the Peripheral Artery Disease Symptom Scale, measured at the end of weeks 3, 4 and 6

Completion date

01/04/2008

Eligibility

Key inclusion criteria

1. Male aged 40 - 80 years
2. Erectile dysfunction (Sexual Health Inventory for Men [SHIM] score less than 21)
3. Peripheral vascular disease (PVD) (confirmed by previous ultrasound studies)

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

Male

Key exclusion criteria

1. Contraindication to PDE 5 inhibitor
2. Inability to undertake an exercise tolerance test

Date of first enrolment

19/09/2007

Date of final enrolment

01/04/2008

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

St Thomas' Hospital
London
United Kingdom
SE1 7EH

Sponsor information

Organisation

Guy's and St Thomas' NHS Foundation Trust (UK)

ROR

<https://ror.org/00j161312>

Funder(s)

Funder type

Charity

Funder Name

The Friend's of Guy's Hospital (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration